Cardiology · Medical Literature
Sex Hormone Influences on Cardiovascular Risk
Abstract
New England Journal of Medicine, Volume 395, Issue 5, Page 518-520, July 30, 2026.
Clinical relevance
What is the nature and clinical significance of sex hormone influences on cardiovascular risk, as discussed in correspondence responding to a 2026 NEJM review on sex hormone therapy and thrombotic/cardiovascular outcomes? __SNAPSHOT__ {"studyDesign":"Correspondence / Letter to the Editor (not a primary research study; commentary responding to a published NEJM Review Article)","setting":"Not reported; correspondence format does not specify an institutional or clinical study setting","sampleSize":"Not applicable (no original data reported in correspondence format)","population":"Not applicable; the correspondence addresses populations relevant to the parent review, which examined individuals receiving sex hormone therapy across multiple indications including contraception, hormone-replacement therapy (HRT), gender-affirming hormone therapy, and oncologic hormone therapy","intervention":"Sex hormone therapies broadly, including estrogen- and progestin-containing oral contraceptives, hormone-replacement therapy (transdermal and oral), testosterone-replacement therapy (TRT), and gender-affirming hormone therapy","comparator":"Not applicable for correspondence format; parent review used comparators relevant to individual studies reviewed","primaryOutcome":"Cardiovascular risk (specific primary outcome not reported in publicly available abstract/citation metadata of this correspondence)","followUp":"Not reported","fundingSource":"Not reported"}
Key findings
Full content of this correspondence is not publicly available; therefore, specific quantitative findings, effect sizes, confidence intervals, and p-values cannot be reported and must not be fabricated. Based on the parent NEJM Review Article (Skeith & Bates, NEJMra2202438, April 2026) to which this correspondence responds: combined oral contraceptives increase VTE risk approximately 3.5-fold and HRT increases VTE risk approximately 2-fold, with the parent review noting that absolute risks remain low in most individuals. Testosterone-replacement therapy was reported not to increase VTE risk in the populations studied, though data in transmasculine individuals were noted as limited. The correspondence piece (pp. 518–520) likely engages critically or supportively with one or more of these findings, but specific arguments, data, or counter-analyses it presents are not reportable from available citation metadata alone. No NNT, NNH, or adjusted effect estimates can be provided for this correspondence specifically.
Practice implications
CRITICAL LIMITATION: Only bibliographic citation metadata is available for this specific correspondence (NEJM 395(5):518–520, July 2026, DOI 10.1056/NEJMc2606372); the abstract and full text are not publicly accessible. Therefore, the specific clinical arguments, data interpretations, and conclusions of this correspondence cannot be reliably summarized or attributed. Clinicians should access the full text directly via NEJM.org. What is established from the parent literature is that sex hormone therapies carry meaningful but heterogeneous cardiovascular and thrombotic risk profiles that depend on hormone type, formulation (oral vs. transdermal), dose, patient sex, age, baseline thrombophilia status, and concomitant cardiovascular risk factors. What this particular correspondence establishes, disputes, nuances, or adds to that body of evidence cannot be determined from available data. Populations not adequately represented in the broader literature include transmasculine individuals on testosterone, patients with pre-existing thrombophilias on gender-affirming therapy, and older patients initiating HRT beyond the established 'timing window.' Practice implications cannot be drawn from this correspondence without full-text review. __LIMITATIONS__ 1. Article type: This is a Correspondence piece (2–3 pages), not a primary research study or systematic review; it cannot establish causality or provide independently powered estimates. 2. Abstract unavailability: The abstract and full text are paywalled; all interpretation here is necessarily extrapolated from citation context and the parent review article, not from the correspondence itself. 3. Correspondence pieces are typically not peer-reviewed with the same rigor as original research or formal review articles. 4. No original patient-level data are expected in a correspondence of this format and length. 5. The correspondence's specific methodological choices, if any data are presented, cannot be assessed. 6. Generalizability of any arguments made cannot be evaluated without full-text access. 7. Funding source and author conflict-of-interest disclosures are not reported in available metadata. __BOTTOM_LINE_CATEGORY__ low_certainty __BOTTOM_LINE__ This NEJM correspondence (Vol. 395, Issue 5, pp. 518–520, July 2026) addresses sex hormone influences on cardiovascular risk in the context of a major 2026 NEJM review on this topic, but its specific conclusions and data cannot be summarized without full-text access. Clinicians managing patients on sex hormone therapies should consult the parent review (Skeith & Bates, NEJMra2202438) for evidence-based guidance, including preferring transdermal estradiol over oral formulations for VTE-risk-sensitive patients, and recognizing that combined oral contraceptives carry an approximately 3.5-fold increased VTE risk. Full-text review of this correspondence is essential before drawing any clinical inferences from it.